Vasopeptidase inhibitors are a new class of drugs that have dual inhibitory effects on two key enzymes involved in the metabolism of vasoactive peptides. Essentially, they inhibit angiotensin-converting enzyme (ACE), thereby blocking the generation of angiotensin II (Ang II); at the same time they prevent the breakdown of natriuretic peptides by the enzyme neutral endopeptidase. The combination of reduction of Ang II on a background of increased natriuretic peptide activity has several potential advantages for the treatment of cardiovascular and renal disease and in particular, hypertension and congestive heart failure (CHF). Several vasopeptidase inhibitors, such as sampatrilat, fasidotril, gemopatrilat and omapatrilat (Vanlev TM , the most clinically developed vasopeptidase inhibitor to date) are under intensive clinical investigation. Recent clinical trials have demonstrated effective antihypertensive activity in hypertension, independent of age, renin and salt status or ethnic origin, and have also highlighted the potential for vasopeptidase inhibition as a new therapeutic modality for the treatment of CHF. Moreover, ongoing research suggests that this new class of drugs may be an important approach, not only for the treatment of hypertension and of conditions associated with overt volume overload but also for ischaemic heart disease.
Introduction
The potent vasodilatory and natriuretic properties of atrial natriuretic peptide (ANP), together with its inhibitory effects on the renin-angiotensin-aldosterone system (RAAS), provides a potentially important therapeutic target for cardiovascular and renal disease. 1 Although the use of natriuretic peptides given as ANP (or brain natriuretic peptide [BNP]) may be of value in some circumstances, as for example in severe congestive heart failure (CHF) on a short-term basis, it is nevertheless also evident that the use of peptides has limited application. Hence, because of the problems associated with application of peptides (parenteral administration, rapid elimination, high commercial costs) considerable efforts have been made in the development of orally active inhibitors to block the breakdown of natriuretic peptides.
Natriuretic peptides are rapidly eliminated from the circulation. In addition to removal through binding to the specific natriuretic peptide clearance receptor, enzymatic inactivation by neutral endopeptidase (EC 24.11) is another major disposal mechanism. 2 Neutral endopeptidase (NEP, also known as neprilysin) is widely distributed; the kidney is a rich source of the enzyme, but it is also found within the central nervous system (CNS), where it appears to be involved in the inactivation of neuropeptides. 3 This enzyme also breaks down enkephalins and inhibitors of this enzyme were originally developed more than two decades ago as 'enkephalinase inhibitors'. 4 Once it was apparent that NEP also hydrolysed natriuretic peptides, these 'enkephalinase' inhibitors were also examined in terms of their renal and cardiovascular effects in experimental models of hypertension and heart failure.
When tested in animals, NEP inhibitors were associated with increases in ANP and urinary cyclic guanosine monophosphate (GMP) and displayed marked natriuretic effects, suggesting potentiation of natriuretic peptide activity. 5, 6 Subsequent work in normal humans confirmed these effects. However, and despite the apparent enhancement of ANP activity, the majority of studies in humans, using mainly the NEP inhibitor candoxatril, found no substantial reductions in blood pressure (BP), either in normotensives or in hypertensives. [7] [8] [9] [10] Limited beneficial effects were also observed in patients with mild chronic heart failure. [11] [12] One possible reason for the limited effectiveness of NEP inhibitors as antihypertensive agents seems to be related to the non-specificity of this enzyme. NEP hydrolyses not only vasodepressor peptides (e.g. natriuretic peptides and bradykinin) but also a variety of vasopressor peptides. 3, 4 In fact, increased plasma levels of angiotensin II (Ang II) 13 and endothelin 14 have been found when candoxatril was given to humans.
While NEP inhibitors increase activity of endogenous natriuretic peptides, the concomitant enhancement of vasopressor peptides, Ang II in particular, is likely to offset their antihypertensive effects. Because of this, there has been considerable interest in combining NEP inhibitors with angiotensin-converting enzyme (ACE) inhibitors, with the expectation that this combination would highlight the effects of natriuretic peptides in the presence of reductions in Ang II.
The benefits of ACE inhibitors (ACE-I) are now well established for both hypertension and for CHF. Given that ANP opposes the deleterious actions of Ang II ( Table 1) , inhibition of ACE activity to reduce Ang II and inhibition of NEP to enhance endogenous natriuretic peptides, theoretically at least,should provide a powerful combination in the treatment of hypertension or CHF. This was confirmed by a series of experiments in animals. A combination of ACE and NEP inhibitors effectively reduced BP in rats with hypertension [15] [16] [17] and displayed beneficial haemodynamic effects in dogs with experimental heart failure. 18, 19 Substantial antihypertensive effects after joint administration of ACE and of NEP inhibitors were then confirmed in humans with essential hypertension. 20, 21 Subsequently, vasopeptidase inhibitors were developed as compounds encapsulating both NEP and ACE inhibitory properties within the same molecule. 22 In the intact animal, administration of vasopeptidase inhibitors was associated with increases in circulating ANP (and BNP in some cases), urinary cyclic GMP and urinary sodium excretion, without a marked effect on potassium excretion, in association with substantial reductions in BP. Significant reductions in BP were reported in the stroke-prone spontaneously hypertensive rat (SHR) 23 and other studies demonstrated significant antihypertensive effects, independent of renin status. 24 Potentially important reductions in pulmonary capillary wedge pressure and in left ventricular (LV) pressures, with increases in cardiac output, were also reported in animals with heart failure. 25 These haemodynamic effects are consistent with those expected after activation of the natriuretic peptide system on a background of reduced activity of Ang II and aldosterone. However, consistently raised plasma levels of ANP have not been found in every investigation; while this may be due to pharmacokinetic issues or maybe a consequence of the haemodynamic effects of concomitant reduction in Ang II, 26 there is additional evidence suggesting that enhanced natriuretic peptide activity may be an important factor in the cardiovascular actions of NEP inhibitors. For example, in dogs with heart failure, the cardiac haemodynamic effects of the NEP inhibitor, omapatrilat (Vanlev TM ), were substantially reduced by the natriuretic peptide receptor antagonist, HS-124. 27 However, to some extent, the effects of neutral endopeptidase inhibitors may also involve other vasoactive peptides ( Figure 1 ). Reductions in bradykinin breakdown have been demonstrated after administration of NEP inhibitors. 28 Since bradykinin is also a substrate for ACE, inhibition of both ACE and NEP is likely to lead to an even greater enhancement of endogenous bradykinin. However, the preservation of bradykinin, in turn, may also enhance the production of nitric oxide (NO) and prostacyclin, with the additional potential benefit of improved blood flow and prevention of platelet aggregation. More recent studies also suggest that vasopeptidase inhibitors may increase circulating levels of adrenomedullin. 29 Adrenomedullin is a potent vasodilator peptide with natriuretic properties, but whether the increases in circulating levels of this peptide are functionally important in the cardiovascular and renal actions of vasopeptidase inhibitors remains to be seen.
Although it is generally assumed that natriuresis and diuresis are an intrinsic part of the actions of vasopeptidase inhibitors, there is now some controversy as to the natriuretic effects of individual substances. Administration of MDL 100,240 in normal humans 30 was associated with a fall in BP, together with the preservation of renal haemodynamics and increased sodium and urinary volume, ANP and cyclic GMP excretion. By contrast, two studies have failed to observe a significant natriuretic effect in response to omapatrilat, both in normotensive subjects 31 and in those with hypertension. 32 The lack of natriuresis after omapatrilat, despite an increase in urinary ANP and reductions in aldosterone, is rather puzzling. One possibility is that any natriuretic effects could be blunted by the associated substantial reductions in BP, due primarily to the vasodilatory effects of NEP inhibition. On the other hand, natriuretic effects have been observed when omapatrilat was given to animals 33 and patients with heart failure. 34 As plasma ANP is substantially raised in CHF, this suggests that the natriuretic responses may well 91 REVIEW Table 1 Contrasting cardiovascular and renal effects of angiotensin II and atrial natriuretic peptide (ANP).
Effects
Angiotensin II ANP Systemic blood pressure depend on the pre-existing levels of ANP and the relative degree of volume overload.
Recent clinical trials -hypertension and congestive heart failure
Given the potential importance of blocking the production of Ang II and promoting the activity of vasodilator and natriuretic peptides, it is not surprising that the majority of clinical studies with vasopeptidase inhibitors target hypertension and CHF as the main indication for this new class of substances ( Table 2) . Heart failure is an increasing public health challenge and, despite recent advances, there is a real need for improvement in treatment. 42 Although several vasopeptidase inhibitors (Table 2 ) are now in an advanced stage of clinical development, omapatrilat is the one that has been most extensively clinically investigated to date. A number of investigations in humans have confirmed that omapatrilat is a potent and longlasting inhibitor of both NEP and ACE. In individuals with essential hypertension, omapatrilat produced dose-related (10-80 mg/day) substantial reductions in average BP; at 80 mg/daily, decreases of systolic blood pressure (SBP) of 20-26 mmHg and of diastolic blood pressure (DBP) of 14-17 mmHg were reported, supporting a once-daily dosing. 43, 44 Comparable reductions in BP after omapatrilat were found in African-American and in Caucasians. 45 This, in conjunction with the early animal experiments demonstrating that the antihypertensive effects of omapatrilat were not related to renin status, 24 suggested that vasopeptidase inhibitors may be particularly effective in salt-sensitive patients -a group of hypertensives who do not respond well to ACE-I monotherapy. That this may be the case was demonstrated by Campese et al., 31 who compared the efficacy of omapatrilat and lisinopril in 'salt-sensitive' hypertensives. Both omapatrilat and lisinopril significantly reduced mean 24-hour ambulatory DBP and SBP; however, omapatrilat produced significantly greater reductions in mean 24-hour ambulatory DBP, ambulatory SBP, and ambulatory mean arteri-al pressure, compared with lisinopril.
Omapatrilat has also been evaluated in patients with CHF, both in short-term and in longer term clinical trials. McClean et al. 34 investigated the effect of omapatrilat in 48 patients with New York Heart Association functional class II or III CHF, with left ventricular ejection fraction (LVEF) <40% and in sinus rhythm, who were randomised to a dose-ranging pilot study of omapatrilat for 12 weeks. Omapatrilat was well tolerated and the results demonstrated an improvement in functional status, as reported by the patient and physician at 12 weeks. Dose-dependent improvements in LVEF and LV end-systolic wall stress were seen, together with a reduction in SBP.
In the IMPRESS trial, 46 omapatrilat was compared with lisinopril alone, on functional capacity and clinical outcome in patients with CHF. In this prospective, randomised, double-blind, parallel group trial, patients were randomly assigned to omapatrilat at a daily target dose of 40 mg (n=289) or lisinopril at a daily target dose of 20 mg (n=284) for 24 weeks.The primary endpoint was improvement in maximum exercise treadmill capacity at week 12. Although there was no difference between the two groups for the primary endpoint, exercise tolerance, omapatrilat displayed a significant benefit in the composite endpoint of death, admission, or discontinuation of study treatment for worsening heart failure. Moreover, the rate of renal dysfunction was significantly less (1.8 vs. 6.1%) in those on omapatrilat.This is of potential beneficial value, since renal function frequently deteriorates during the progression of CHF, and renal impairment is one of the most powerful predictors of adverse prognosis in patients with CHF. 47 The recently reported larger scale Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) study 48 has now demonstrated that omapatrilat was as effective as enalapril in terms of incidence of death and hospitilisation due to worsening heart failure. OVER-TURE, a randomised, double-blind, international clinical trial was conducted in approximately 40 REVIEW Table 2 Characteristics of selected vasopeptidase inhibitors under clinical development.
Substance Source Comments/Status
Sampatrilat Shire Pharma Produced sustained reductions in blood pressure in African-Americans. 35 Currently under clinical development after reformulation to improve bioavailability Gemopatrilat
Bristol-Myers-Squibb Antihypertensive actions, good oral efficacy. 36 Phase I/II clinical trials for hypertension MDL-100240
Aventis Pharma High affinity inhibitor of both ACE and neutral endopeptidase; antihypertensive and natriuretic. 30, 37 Under clinical investigation for hypertension and congestive heart failure Fasidotril Lilly/BioProject Moderate antihypertensive effects. Natriuretic in animal experiments. 38 Improved survival of rats after myocardial infarction. 39 countries and included 5,770 patients with moderate-to-severe heart failure. Patients were randomised to receive either omapatrilat (10 mg once-daily) or enalapril (25 mg twice-daily), with a minimum follow-up of eight months. Dosages were increased, as tolerated, to 20 mg or 40 mg of omapatrilat once-daily and 5 mg or 10 mg of enalapril twice-daily. Omapatrilat and enalapril produced similar treatment outcomes. Specifically, preliminary data showed that for the primary endpoint, the incidence of death or hospitalisation due to worsening heart failure was 31.7% with omapatrilat and 33.7% with enalapril. Despite these favourable results, however, there is concern about the side-effect profile of omapatrilat and specifically about the greater frequency of angio-oedema compared with ACE-I alone. Angio-oedema (a swelling that generally affects the face, throat, lips, tongue or larynx) is a well-documented, but rare, serious adverse effect in patients taking ACE-I, occurring in 0.1% to 0.5% of individuals. 49 In the Intramural low molecular weight heparin for Prevention of Restenosis Study (IMPRESS), 46 the prevalence of angio-oedema in those on omapatrilat was dose-dependent and at 20 mg/day was more than three times more common than that observed with ACE-I. In the OVERTURE trial, 48 both omapatrilat and enalapril were generally safe and well tolerated; however, the incidence of angio-oedema, was higher in the omapatrilat-treated patients than in the enalapriltreated patients (0.8% vs. 0.5%).
The exact reasons for the development of angio-oedema are not known, but may be related to enhancement of bradykinin. Plasma bradykinin concentrations can rise more than 10-fold during acute attacks of angio-oedema associated with an ACE-I. 50 Bradykinin is also degraded by NEP, and hence a dual ACE and NEP inhibitor may well be associated with a higher level of bradykinin and a higher risk of angio-oedema in susceptible individuals.
Because of this, the Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) study was set up to compare omapatrilat against enalapril on the incidence of angio-oedema in patients with hypertension. The OCTAVE study included approximately 25,000 hypertensive patients and was designed to assess multiple treatment strategies with omapatrilat, vs. the ACE-I enalapril. Preliminary results have now been reported. 51 This study has demonstrated consistently greater SBP reductions with omapatrilat in all patient groups by an average of 3 mmHg, whether used alone or in combination with existing antihypertensive therapies. The proportion of patients who reached BP of <140 mmHg SBP and <90 mmHg DBP was consistently about nine percentage points higher with omapatrilat than with enalapril. Greater SBP reductions were also consistently observed with omapatrilat, than with enalapril, across a broad range of patient types, including people with diabetes, renal disease, severe hypertension, isolated systolic hypertension, and prior coronary or cerebrovascular events. The safety profiles of omapatrilat and enalapril were similar, although there was a higher risk of angio-oedema in the omapatrilat-treated patients. The most common manifestation of angio-oedema in patients treated with omapatrilat or enalapril was face or lip swelling. The overall incidence of angio-oedema over 24 weeks was 2.17% with omapatrilat and 0.68% with enalapril. This study also confirms a much higher rate of angio-oedema in black patients on omapatrilat compared with enalapril (5.54% with omapatrilat vs. 1.62% with enalapril) than in non-black patients (1.78% with omapatrilat vs. 0.55% with enalapril).
Although the angio-oedema developed soon after omapatrilat treatment, and it responded to appropriate treatment, it is, nevertheless, a potentially serious adverse effect and raises questions on the use of omapatrilat as a first-line drug for hypertension, especially in Afro-Caribbeans.
Clearly, further information on the specific factors which predispose individuals to the development of angio-oedema is required to fully assess the risk/benefit profile when considering the use of this vasopeptidase inhibitor. Moreover, it remains to be seen whether the high rate of angiooedema is specific to omapatrilat or whether it is a common feature of vasopeptidase inhibitors.
Nonetheless, given the potential favourable effects of vasopeptidase inhibitors (Table 3) , it is likely that this new class of drugs may well become an important approach to the treatment of hypertension and of conditions associated with overt volume overload. At the same time, there is also increasing experimental evidence to suggest that vasopeptidase inhibitors may also have beneficial effects on ischaemic heart disease. 39, 52, 53 The Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial is now underway to see whether omapatrilat will reduce cardiovascular morbidity and mortality in older hypertensives (>65 years) at higher risk of atherosclerotic events. 54 
